Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20034776 | 0.87 | FAAH (0.35) | — | |
| SCHEMBL18392549 | 0.83 | ALDH1A1 (0.33) | LMNA | |
| SCHEMBL20931040 | 0.82 | MEN1 (0.31) | — | |
| SCHEMBL24049292 | 0.77 | FAAH (0.33) | — | |
| SCHEMBL23340953 | 0.76 | FAAH (0.35) | — | |
| SCHEMBL21886086 | 0.75 | — | — | |
| SCHEMBL23690144 | 0.75 | LMNA (0.32) | LMNA | |
| SCHEMBL23153542 | 0.74 | FAAH (0.31) | — | |
| SCHEMBL22005355 | 0.74 | FAAH (0.34) | — | |
| SCHEMBL19991910 | 0.74 | MGLL (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746086-B2 | Non-aggregating heptamethine cyanine fluorophores for in vivo imaging | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220009938-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| US-20210128777-A1 | ADDITIVE ABLE TO PROVIDE UNDERWATER ADHESION | BAXTER HEALTHCARE SA (CH) | 2021-05-06 | — | — | US | disclosed |
| US-10912859-B2 | Additive able to provide underwater adhesion | BAXTER INTERNATIONAL INC. (US) | 2021-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746086-B2 | Non-aggregating heptamethine cyanine fluorophores for in vivo imaging | CNDP2, MSN, CHAT | LMNA 3708/4885 |
| US-20220009938-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | SCN11A, SCN10A, SCN3A | LMNA 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.